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Functional status as a prognostic factor for primary
revascularization for critical limb ischemia
H. C. Flu, MD,a J. H. P. Lardenoye, MD, PhD,a E. J. Veen, MD,b D. P. Van Berge Henegouwen, MD, PhD,b
and J. F.Hamming,MD, PhD,a Leiden and Tilburg, The Netherlands
Background: Lower extremity arterial revascularization (LEAR) is the gold-standard for critical lower limb ischemia
(CLI). The goal of this study was twofold. First, we evaluated the long-term functional status of patients undergoing
primary LEAR for CLI. Second, prognostic factors of long-term functional status and survival after primary LEAR for
CLI were assessed.
Methods: All primary LEAR procedures were analyzed. Patients were stratified by preoperative functional status:
ambulatory (group I) vs nonambulatory (group II). Patients were followed-up after 3 and 6 years. Adverse events (AEs)
were categorized according to predefined standards: minor, surgical, failed revascularization, and systemic. Associated
patient demographic/clinical data were analyzed using univariate and multivariate methods.
Results: There were 106 LEAR patients (group I: n  42, 40% vs group II: n  64, 60%). Group II patients were
significantly older (75 vs 62 years; P  .00), were classified ASA 3-4 more frequently (78% vs 52%; P < .02), had more
cardiac disease (n  42, 66% vs n  10, 24%; P  .00), renal disease (n  26, 41% vs n  7, 17%; P  .00), diabetes (n 
36, 56% vs n  8, 19%; P  .00), hypertension (n  47, 73% vs n  13, 31%; P  .00) and severe CLI (n  42, 66% vs
n 18, 38%; P< .01). Group II patients had a higher incidence of death (65.6% vs 14.3%; P .00), minor AEs (n 38,
26% vs n 10, 22%; P .00), surgical AEs (n 48, 33% vs n 12, 26%; P< .02) and systemic AEs (n 24, 86% vs n
4, 9%; P < .02). Also more unplanned reinterventions occurred in group II (n  148, 76% vs n  47, 24%; P  .00).
Nonambulatory status was a multivariate independent predictor of nonambulatory status after LEAR during 6 years
follow-up (odds ration [OR[: 21.47; 95% confidence interval [CI]: 2.76-166.77; P .00). Pulmonary disease (OR: 7.49;
95% CI: 2.17-25.80; P  .00), not prescribing -blockers (OR: 4.67; 95% CI: 1.28-17.03; P < .02), nonambulatory
status (OR: 22.99; 95% CI: 6.27-84.24; P  .00), and systemic AEs (OR: 9.66; 95% CI: 1.84-50.57; P < .01) were
independent predictors of death. Functional status was not improved in group II after long-term follow-up.
Conclusion:Nonambulatory patients suffer from extensive comorbid conditions. They are accompanied with an increased
occurrence of AEs, unplanned reinterventions, and poor long-term survival rates. Successful LEAR did not improve their
functional status after 6 years. This emphasizes that attempts for limb salvage must be carefully considered in these
patients. ( J Vasc Surg 2010;51:360-71.)With aging of the population and improved medical
care, vascular physicians face an ever increasing number of
elderly patients with progressed forms of peripheral arterial
occlusive disease (PAOD).1 There will be approximately
between 500 and 1000 new cases of critical lower limb
ischemia (CLI) every year in a European or North Ameri-
can population of 1 million, and the prevalence has been
estimated to be 1 per 2500 inhabitants.2,3 These patients
represent about 1% of the total number of patients with
PAOD.2,3 They frequently have arterial disease affecting
several vascular beds and suffer from other significant co-
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360morbidities such as diabetes mellitus, respiratory disease,
and renal disease.
The treatment options of CLI patients can broadly be
classified into optimal medical management and invasive
treatment. The optimal medical management often consists
of lifestyle modification (smoking cessation, dietary man-
agement, and supervised walking exercise) and medical
comanagement (lipid-lowering agents, antiplatelet agents,
heart rate and blood pressure regulation).2-6 It has been
shown to be effective in decreasing the risk of cardiovascu-
lar morbidity and improving long-term survival.2-4,7,8 The
invasive treatment consists of vascular (endovascular
and/or surgical treatment) and nonvascular (drainage, mi-
nor and major amputations) treatment.
The primary goals of CLI treatment are to relieve
ischemic pain, heal ischemic ulcers, prevent limb loss, im-
prove patient function and quality of life (QOL), and
prolong patient survival. However, most CLI patients have
a tremendous disease burden, with poor baseline function,
including loss of functional status and ability to live inde-
pendently. Their prognosis is associated with their multiple
comorbid diseases, which may also influence the patient’s
QOL2,9 and functional status. The 5-year survival of these
CLI patients is relatively poor and compares with patients
with cancer (50%).10,11
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(LEAR) in patients with CLI is indicated for patients who
are independently functioning without extensive comorbid
conditions. However, LEAR in nonambulatory CLI pa-
tients with extensive comorbid conditions without a likeli-
hood that they will benefit functionally in terms of main-
taining or improving ambulatory status and pain relief
remains questionable. In selected high-risk patients, a
primary major amputation after CLI is thought by some
to be a better option rather than sequential hospital
admissions with reinterventions, wound complications,
and weeks of hospitalization due to failed revasculariza-
tion attempts,2,3,12-17 a topic that was addressed previ-
ously by Moore et al18,19 in the 1980s.
The purpose of this study was twofold. First, we at-
tempted to determine the outcome of functional status and
patient survival undergoing primary LEAR for CLI. Sec-
ond, we attempted to assess which prognostic factors may
be of importance in determining functional status and
survival after primary LEAR.
METHODS
Patients
This study was evaluated and approved by the institu-
tional review board. All 106 consecutive patients without a
history of LEAR or amputations were included. Criteria for
inclusion was critical limb ischemia (CLI); ischemic rest
pain (Fontaine stage 3) with a resting AP 40mmHg; and
gangrene or nonhealing ischemic ulceration (Fontaine
stage 4) with a resting AP  60 mm Hg, corresponding
with categories 4, 5, and 6 of the Society of Vascular
Surgery/North American Chapter of the International So-
ciety for Cardiovascular surgery (SVS/ISCVS) standards6
and according to the Trans-Atlantic Inter-Society Consen-
sus Document on Management of Peripheral Arterial Dis-
ease (TASC)2,3 guidelines. In case of in diabetic patients,
CLI was diagnosed by clinical findings in combination with
signs of diminished perfusion and radiologic diagnostics
(computed tomography angiography/digital subtraction
angiography). The included femoral popliteal lesions were
according to the TASC-classification type B, C, or D for
plaque morphology.2,3
Functional status
As listed in Appendix I, online only, the functional
status was evaluated according to the functional indepen-
dence measure.20 It was determined before (inclusion pe-
riod: January 2001 till January 2003) and after (3 years and
6 years) primary LEAR. The patients were followed up at
the time of their death to determine their functional status.
Risk factors and comorbidity
Risk factors, the American Society of Anesthesiologists
(ASA) classification,21 and body mass index (BMI)22 were
registered prospectively during the admission intake. Risk
factor classification and management was according to theSVS/ISCVS standards, TASC, and AHA/ACC4,23 guide-
lines.
Medical comanagement
Medication use according to the TASC and AHA/
ACC reporting standards was listed by the patients at
baseline. Prescribed drugs recorded for purposes of analysis
were reviewed and classified according to the following
categories: antiplatelet agents, -blockers, and HMG-
CoA-reductase inhibitors.
Invasive treatment of CLI
As listed in Table II, revascularization was divided in
primary LEAR and unplanned reinterventions. LEAR was
divided in percutaneous transluminal angioplasties (PTAs)
and bypass graft procedures (BGPs). PTAs were carried out
by conventional balloon dilatation of the lesion with or
without stent placement and were performed under local
anesthesia with or without sedation. Bypass graft proce-
dures (BGP) were performed according to standard vascu-
lar techniques, using preferably reversed vein for femoral
popliteal (supra- and infragenual) and crural BGPs. The
BGP patency was determined by duplex ultrasound exam-
ination and ankle-brachial indices in all patients 4 weeks
after LEAR. The definition of primary and secondary pa-
tency, the decision to intervene and the type of reinterven-
tion were driven by the SVS/ISCVS and TASC reporting
standards. All operations were performed by or under the
supervision of a vascular surgeon.
Adverse events
In The Netherlands, the Association of Surgeons of the
Netherlands (ASN) has agreed on one common definition
of Aes.24 This definition (Appendix II, online only) differs
from that used in other studies because it has been chosen
with the explicit aim of excluding subjective judgment on
cause and effect, and right and wrong. This definition did
not change during the study period. As listed in Appendices
II and III, online only, the AEs were subdivided into four
groups: minor, surgical, failed revascularization, and sys-
temic.
Registration and statistical analysis
Patient information was registered prospectively in an
electronic patient file (Oracle database) used for all patients
during their admission intake. Statistical analyses were per-
formed through a computerized software package, using
SPSS 16.0 for Windows. Patient characteristics, reinterven-
tions, and AEs were analyzed with the Mann-Whitney
U-Test. Univariate analyses (2 and unpaired Student
t test) and multivariate logistic regression models (Cox
regression) were conducted. The Kaplan-Meier survival
method was used to calculate the time curve of the
cumulative primary and secondary patency, limb salvage,
and patient survival rates determined at regular intervals
after primary LEAR. The log-rank test was used for
comparison of these survival rates. For all statistical
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RESULTS
Patients’ characteristics
Comorbidity. Fifty-six men (53%) and 50 women
(47%) underwent LEAR (Table I). Forty-two (40%) repre-
sented group I and 64 (60%) group II. Mean age was 70
(range 47-93) years (group I: 62 range 47-85 years vs
Table I. Patient characteristics of all patients with primary
Characteristics Total
Gender
Male 56 (53)
Female 50 (47)
Age
Mean, years 70
(Min;max), years (47;93)
BMI
Normal 60 (57)
Overweight 40 (38)
Obesity 6 (6)
ASA-classification
Classification 2 34 (32)
Classification 3 68 (64)
Classification 4 4 (4)
Comorbidity
Cardiac disease 52 (49)
Pulmonary disease 33 (31)
Renal disease 33 (31)
Diabetes mellitus 44 (42)
Hypertension 60 (57)
Tobacco use 65 (61)
Hyperlipidemia 46 (43)
Carotid disease 24 (23)
SVS/ISCVS
Risk factors
Median (SD), n 3.4 (1.8)
(Min;max), n (1;8)
Risk score
Mean (SD) 0.78 (0.56)
(Min;max) (0.0;2.3)
Secondary prevention
Antiplatelet agent 81 (76)
-blocker 82 (77)
HMG-CoA-reductase inhibitors 91 (86)
ABI at baseline mean (SD) 0.46 (0.22)
Fontaine-classification
Classification 3 48 (45)
Classification 4 58 (55)
TASC-classification
Femoral popliteal lesions
Type B lesion 39 (37)
Type C lesion 16 (15)
Type D lesion 51 (48)
LEAR, Lower extremity arterial revascularization; CLI, critical limb isch
anesthesiologists; BMI, bodymass index; normal, BMI 18.5-24.9 kg/m2; ov
of Vascular Surgery/North American Chapter, International Society of Card
Consensus Document on Management of Peripheral Arterial Disease.
Data are presented as n and (%), unless otherwise specified.
a2 test.
bMann-Whitney test.group II: 75 range 55-93 years, P  .00). There was adifference concerning the ASA-classification; 68% of all
patients (n  72) were ASA 3-4 (group I: n  22, 52% vs
group II: n  50, 78%, P  .02). There was no difference
with regard to the BMI, 44% of all patients (n  46) were
overweight or obese (group I: n  15, 36% vs group II:
n  31, 48%, P  .09). Concerning the comorbidity,
more patients in group II suffered from cardiac disease
(P .00), renal disease (P .01), diabetes mellitus (P
.00), and hypertension (P  .00). More patients in
stratified by functional status prior to LEAR
Group I Group II P value
.13a
26 (62) 30 (47)
16 (38) 34 (53)
62 75 .00a
(47;85) (55;93)
.09a
27 (64) 33 (52)
15 (36) 25 (39)
0 (0) 6 (9)
.02a
20 (48) 14 (22)
21 (50) 47 (73)
1 (2) 3 (5)
10 (24) 42 (66) .00a
13 (31) 20 (31) .97a
7 (17) 26 (41) .01a
8 (19) 36 (56) .00a
13 (31) 47 (73) .00a
23 (55) 32 (50) .00a
26 (62) 20 (31) .00a
7 (17) 17 (27) .23a
2 (1.8) 4 (1.8) .01b
(1;8) (1;8)
0.50 (0.54) 0.97 (0.55) .00a
(0.0;1.8) (0.1;2.3)
30 (71) 51 (80) .33a
32 (76) 50 (78) .82a
36 (86) 55 (86) .97a
0.47 (0.21) 0.45 (0.22) .17b
.01a
26 (62) 22 (34)
16 (38) 42 (66)
.23a
19 (45) 20 (31)
7 (17) 9 (14)
16 (38) 35 (55)
group I, independent; group II, dependent; ASA, American society of
ht, BMI 25.0-29.9 kg/m2; obesity, BMI 30 kg/m2; SVS-ISCVS, Society
ular Surgery;ABI, ankle-brachial index; TASC,Trans-Atlantic Inter-SocietyCLI
emia;
erweig
iovascgroup I were current smokers (P  .00) and suffered
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patient SVS-ISCVS risk score of 0.78 (group I: 0.50 vs
group II: 0.97, P  .00).
Medical comanagement. With respect to the medical
comanagement (Table I), no difference was identified:
antiplatelet agents (group I: n  30, 71% vs group II: n 
51, 80%, P  .33), -blockers (group I: n  32, 76% vs
group II: n 50, 78%, P .82), and HMG-CoA-reductase
inhibitors (group I: n 36, 86% vs group II: n 55, 86%,
P  0.97). Between 75% and 86% of the patients were on
target of the TASC and AHA/ACC reporting guidelines
concerning the medical comanagement.
Peripheral arterial occlusive disease. There was a
difference concerning the Fontaine-classification (Table I):
45% (n  45) were classified Fontaine 3 and 55% (n  58)
Fontaine 4 (Fontaine 3: group I: n  26, 62% vs group II:
n 22, 34% and Fontaine 4: group I: n 16, 38% vs group
II: n 42, 66% P .01). There was no difference (Table I)
concerning the TASC type of femoral popliteal lesion
(TASC B: group I: n  19, 45% vs group II: n  20, 31%
Table II. Summary of primary LEAR and unplanned
reinterventions of all patients with primary CLI stratified
by functional status after LEAR
Characteristics Total Group I Group II P value
Primary LEAR 106 (35) 42 (40) 64 (60) .10a
PTA 39 (37) 20 (47) 19 (30) .01a
Femoral popliteal:
type B lesion 39 (37) 20 (47) 19 (30)
BGP 67 (63) 23 (55) 45 (70) .07a
Femoral popliteal SG 16 (15) 7 (17) 9 (14)
Femoral popliteal IG 30 (28) 12 (29) 18 (28)
Femoral crural 21 (20) 3 (7) 18 (28)
Unplanned
reinterventions 195 (65) 47 (24) 148 (76) .00b
Vascular 89 (46) 31 (66) 58 (38) .13b
RoBGP 28 (14) 12 (26) 16 (57)
RiBGP 2 (1) 0 (0) 2 (1)
PTA 28 (14) 7 (15) 21 (14)
BGP 22 (11) 11 (23) 11 (7)
Hemorrhage 9 (5) 1 (2) 8 (5)
Nonvascular 106 (54) 16 (34) 90 (61) .01b
Wound drainage 9 (5) 2 (4) 7 (5)
Skin grafting 8 (4) 2 (4) 6 (4)
Necrotectomy 40 (21) 8 (17) 32 (22)
Minor amputation 37 (19) 4 (9) 33 (22)
BKA 3 (2) 0 (0) 3 (2)
AKA 9 (5) 0 (0) 9 (6)
Patients with
reinterventions 58 (55) 15 (36) 43 (67) .00a
Total interventions 301 (100) 89 (30) 212 (70) .00b
CLI, Critical limb ischemia; LEAR, lower extremity arterial revasculariza-
tion; BGP, bypass graft procedure; SG, supragenual; IG, infragenual; PTA,
percutaneous transluminal angioplasty; group I, ambulatory; group II,
nonambulatory; RoBGP, revascularization of bypass graft; RiBGP, removal
infected bypass graft; BKA, below knee amputation; AKA, above knee
amputation.
Data are presented as n and (%), unless otherwise specified.
a2 test.
bMann-Whitney test.and TASC C: group I: n  7, 17% vs group II: n  9, 14%and TASC D: group I: n  16, 38% vs group II: n  35,
55%, P  .23).
Invasive treatment of CLI
Primary LEAR. There was a difference with regard to
PTAs (n  39, 37%), (group I: n  20, 47% vs group II:
n  19, 30%, P  .01). A total of 67 primary BGPs (64%):
reversed vein was used in 57 (85%) and PTFE was used in
10 BGPs (15%). There was no difference (Table II) con-
cerning BGPs (femoral popliteal SG group I: n 7, 17% vs
group II: n 9, 14% and femoral popliteal IG group I: n
12, 29% vs group II: n 18, 28% and femoral crural group
I: n  3, 7% vs group II: n  18, 28%, P  .07).
Reinterventions. There was a difference (Table II)
among the patients who underwent reinterventions (group
I: n  15, 36% vs group II: n  43, 67%, P  .00). There
was also a difference in all reinterventions (total: n  195,
65%; group I: n 47, 24% vs group II: n 148, 76%, P
.00; vascular: n  89, 46%; group I: n  31, 66% vs group
II: n  58, 38%, P  .13 and nonvascular: n  106, 54%;
group I: n  16, 34% vs group II: n  90, 61%, P  .01).
All major amputations (BKA: n  3, 2% and AKA: n  9,
6%) occurred in group II patients.
In hospital adverse events. One hundred ninety-two
AEs (Table III) occurred in 62 patients (58%). There was a
difference with regard to the patients who underwent AEs
(group I: n 14, 33% vs group II: n  48, 75%, P .00).
There was also a difference in the total of AEs (group I: n
46, 24% vs group II: n 146, 76%, P .00; minor: n 48,
25%; group I: n  10, 22% vs group II: n  38, 26%, P 
.00; surgical: n  60, 31%; group I: n  12, 26% vs group
II: n  48, 33%, P  .02; systemic: n  28, 15%; group I:
n  4, 9% vs group II: n  24, 86%, P .02).
Functional status
Before primary LEAR, 40% of the patients (42 of 106)
were ambulatory and 60% (64 of 106) were nonambulatory
(Table IV, Figs 1 and 2).
Follow-up at 3 years. Forty-three percent (n  46)
were ambulatory, 30% (n  32) nonambulatory, and 27%
(n  28) died (Figs 1, 2, and 3). Of the 42 (40%) ambula-
tory patients before LEAR, 38 (90%) remained ambulatory,
two (5%) worsened to nonambulatory status, and two (5%)
were not alive at 3 years. Of the 64 (60%) nonambulatory
patients before LEAR, 30 (47%) remained nonambulatory,
eight (13%) improved their status to ambulatory, and 26
(41%) were not alive at 3 years. Overall, preoperative am-
bulatory status was maintained in 87% (n  68) of survi-
vors, worsened in 2.6% (n 2), and improved in 10% (n
8) of survivors at 3 years.
Follow-up at 6 years. Thirty-three percent (n  35)
were ambulatory, 22% (n  23) were nonambulatory, and
45% (n  48) had died (Figs 1, 2, and 3). Of the 42 (40%)
ambulatory patients before LEAR, 35 (83%) remained
ambulatory, one (2%) worsened to the nonambulatory
status, and six (14%) were not alive at 6 years. Of the 64
nonambulatory patients (60%) before LEAR, 22 (34%)
remained nonambulatory and 42 (66%) were not alive at 6
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tained in 98% (n  57) and worsened in 2% (n  1) of the
survivors at 6 years.
Predictive factors
Table V and Fig 3 list the relationship between patient
characteristics and functional and living status after LEAR.
Functional status. BMI, diabetes mellitus, and nonam-
bulatory status were significantly correlated with nonambu-
Table III. Summary of adverse events of all patients with
Characteristics Total
Minor 48 (25)
Line infection 1 (1)
Urinary tract infection 13 (7)
Blister/ulcer 2 (1)
Other miscellaneous 6 (3)
Delay to operation room 8 (4)
Delay to medical doctor 5 (3)
Error in judgment 5 (3)
Incomplete hospital record 7 (4)
Surgical 60 (31)
Wound infection 25 (13)
Wound dehiscence 6 (3)
Hemorrhage 18 (9)
Gangrene 10 (5)
Other 1 (1)
Failed revascularization 56 (29)
Failed BGP 46 (24)
Failed PTA 10 (5)
Systemic 28 (15)
Respiratory Insufficiency 2 (1)
Pneumonia 3 (2)
Arrhythmia 3 (2)
Cardiac arrest 3 (2)
Cardiogenic shock 3 (2)
Congestive heart failure 4 (2)
Myocardial infarction 4 (2)
Shock 1 (1)
Septicemia 2 (1)
Stroke 3 (2)
Patients
With adverse events 62 (58)
Who died during follow-up 48 (45)
Total adverse events 192 (100)
LEAR, Lower extremity arterial revascularization; group I, ambulatory;
transluminal angioplasty.
Data are presented as n and (%), unless otherwise specified.
a2 test.
bMann-Whitney test.
Table IV. Functional status of all patients prior primary L
Prior primary LEAR After 3 years of fo
Status Total Ambulatory Nonambul
Ambulatory 42 (40) 38 (90) 2 (5)
Nonambulatory 64 (60) 8 (13) 30 (47
Total 106 (100) 46 (43) 32 (30
LEAR, Lower extremity arterial revascularization.
Data are presented as n and (%), unless otherwise specified.latory status after 6 years. Including these variables in themultivariate analysis, only nonambulatory status (OR:
21.47; 95% CI: 2.76-166.77; P  .00) remained an inde-
pendent predictive risk factor for postoperative nonambu-
latory status.
Long-term survival. ASA-3, Fontaine-4, cardiac, pul-
monary, renal, and carotid disease, diabetes mellitus, hyper-
tension, not prescribing -blockers, nonambulatory status,
the occurrence of reinterventions, and AEs were signifi-
cantly correlated with early death 6 years after LEAR.
ary CLI stratified by functional status prior to LEAR
Group I Group II P value
10 (22) 38 (26) .00b
0 (0) 1 (1)
3 (7) 10 (7)
0 (0) 2 (1)
1 (2) 6 (4)
0 (0) 8 (5)
3 (7) 2 (1)
1 (2) 4 (3)
2 (4) 5 (3)
12 (26) 48 (33) .02b
4 (9) 21 (14)
2 (4) 4 (3)
5 (11) 13 (9)
0 (0) 10 (7)
1 (2) 0 (0)
20 (43) 36 (25) .16b
19 (41) 27 (18)
1 (2) 9 (6)
4 (9) 24 (86) .02b
0 (0) 2 (1)
1 (2) 2 (1)
0 (0) 3 (2)
1 (2) 2 (1)
0 (0) 3 (2)
0 (0) 4 (3)
0 (0) 4 (3)
1 (2) 0 (0)
0 (0) 2 (1)
1 (2) 2 (1)
14 (33) 48 (75) .00a
6 (14) 42 (66) .00a
46 (24) 146 (76) .00b
II, nonambulatory; BGP, bypass graft procedure; PTA, percutaneous
and during follow-up: 3 years and 6 years
p After 6 years of follow-up
Died Ambulatory Nonambulatory Died
2 (5) 35 (76) 5 (11) 6 (13)
26 (41) 0 (0) 18 (56) 14 (44)
28 (27) 35 (45) 23 (29) 20 (26)prim
groupEAR
llow-u
atory
)
)Including these variables in the multivariate analysis, pul-
ring
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not prescribing -blockers (OR: 4.67; 95%CI: 1.28-17.03;
P  .02), nonambulatory status (OR: 22.99; 95% CI:
6.27-84.24; P  .00), and systemic AEs (OR: 9.66; 95%
CI: 1.84-50.57; P .01) remained independent predictive
risk factors for early death.
Patency, limb salvage, and survival. The AE “failed
revascularization” occurred 56 times (group I: n 20, 43%
vs group II: n 36, 35%, P .16) in these series. There was
no difference (Table VI) concerning primary patency rates
of all PTAs after 6 years (all: 87.7%; group I: 95.7% vs group
II: 82.4%, P  .63). There was also no difference (Table
VI) concerning primary and secondary patency rates of all
BGPs after 6 years (all: 52.6%; group I: 77.4% vs group II:
35.7%, P .25) and (all: 77.6%; group I: 87.9% vs group II:
Fig 1. Functional status of all critical lower limb ischem
LEAR and during follow-up (3 and 6 years).
Fig 2. Functional status of all critical lower limb ischem
lower extremity arterial revascularization (LEAR) and du72.2%, P  .30), respectively.There was a difference concerning limb salvage rates of
all limbs (Table VI and Fig 4) after 6 years (all: 87.5%;
group I: 100% vs group II: 85.2%, P  .03).
Forty-eight patients died (30 days: n  8, 28%; 30
days and 3 years]: n 20, 42%;3 - and 6 years]: n  20,
42%) after LEAR (Tables VI and VII). There was a differ-
ence (Table VI and Fig 5) concerning the patient survival
rates after 6 years (all: 59.2%; group I: 87.8% vs group II:
38.6%, P  .00).
DISCUSSION
Contemporary care of CLI consists of near universal
attempts of LEAR. The overall decision for limb salvage
must consider not only the foot and the technical aspects of
LEAR but also the patient’s comorbidity and expected
I) patients stratified by functional status before primary
I) patients stratified by functional status before primary
follow-up (3 and 6 years).ia (CLia (CLoutcomes.25 This information can and must have serious
JOURNAL OF VASCULAR SURGERY
February 2010366 Flu et alinfluence on the decision concerning which exact therapy is
the best approach for each individual CLI patient. This
study was conducted to obtain insight in functional status
and long-term survival after LEAR in CLI patients. Fur-
thermore, several important prognostic factors influencing
functional status and survival in this specific patient popu-
lation were assessed.
Functional status prior LEAR: ambulatory vs
nonambulatory
Patient characteristics. Assessing patients’ character-
istics reveals that the nonambulatory patients were high-
risk patients suffering from extensive comorbid conditions
and severe CLI. Compared with the ambulatory patients,
the nonambulatory patients were characterized by a higher
SVS/ISCVS risk score and ASA classification 3-4 at time of
LEAR. They were older, suffered from cardiac disease,
renal disease, hypertension, hyperlipidemia, and diabetes
mellitus. Also, most of the nonambulatory patients in this
study were diagnosed with Fontaine classification 4, the
most severe form of CLI.
Reintervention and adverse events after primary
LEAR for CLI. Almost all reinterventions in the postop-
erative period were performed in the nonambulatory pa-
tient group. The reintervention and AE rate in the nonam-
Fig 3. Univariate and multivariate positive predictin
(death).bulatory patient group is significantly higher comparedwith the ambulant patient group. This is due to the more
severe comorbid condition of these patients. However, the
high reintervention rate in the nonambulatory patients
implicates an increased risk of new AEs, total length of stay,
increased morbidity, and health care costs. Furthermore,
these reinterventions and AEs result in an increased physical
and mental burden for the CLI patient. The risk of postop-
erative AEs is directly related to preoperative general health
status and presence of severe comorbidity.26 Reports have
also confirmed that patients undergoing LEAR have an
increased risk of perioperative cardiac AEs.27,28
Limb salvage. Results of the traditional measures of
outcome of LEAR were primary and secondary patency
rates of 52.6% and 77.6%, respectively, and a total limb
salvage rate of 87.5%. They were in correspondence with
findings in other reports.2,29-31
Important to stress is that the limb salvage in the
nonambulatory patients was significantly worse after 6
years; all unplanned major amputations only occurred in
these patients.
Functional status and long-term survival after
primary LEAR for CLI
In this study, at time of primary LEAR, 40% of the CLI
patients were ambulatory and 60% non ambulatory. After
tors of functional (nonambulatory) and living statusg faclong-term follow-up (6 years), 48 patients died (45%) and
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Volume 51, Number 2 Flu et al 367for those patients who survive, 60% was ambulatory and
40% nonambulatory after primary LEAR.
Ambulatory. Ambulatory status at time of LEAR in
CLI patients is a positive predicting factor concerning
long-term functional status.12,29,32-34 This was also the
finding in our study; the status of patients who were ambu-
latory prior to LEAR (40%) was rarely worsened by LEAR
after 3 and 6 years, respectively. Also most of the patients in
this group (86%) were alive after 6 years.
Nonambulatory. The findings of this study implicate
that the majority of non ambulant patients with satisfactory
technical outcome after LEAR, including limb salvage, will
experience no improvement in functional status. These
findings are in agreement with the literature.29,32,33 In this
study, the patients’ nonambulatory status at time of LEAR
was an independent predictive risk factor of functional
status after 6 years. Also, BMI (overweight/obesity) and
DM were correlated with nonambulatory status after 6
years. Although there may be compelling reasons to con-
Table V. Univariate and multivariate Cox regression analy
living status
Characteristics
Univariate r
OR 95% CI
Functional status Nonambulatory
BMI
Overweight/obesity 13.00 (2.03-82.9
Comorbidity
Diabetes mellitus 2.74 (1.06-7.10
Functional status
Nonambulatory 21.47 (2.76-166
Living status
Death
ASA-classification
Classification 3 3.05 (1.36-6.83
Fontaine-classification
Classification 4 2.09 (0.95-4.59
Comorbidity
Cardiac disease 3.80 (1.69-8.52
Pulmonary disease 3.61 (1.51-8.61
Renal disease 3.61 (1.51-8.61
Diabetes mellitus 2.23 (1.04-4.90
Hypertension 2.52 (1.13-5.61
Carotid disease 3.12 (1.19-8.14
Secondary preventiona
-blocker 2.47 (0.97-6.31
Functional status
Nonambulatory 11.45 (4.18-31.3
Secondary procedures 2.46 (1.11-5.43
Adverse events 3.69 (1.60-8.49
Minor 3.01 (1.36-6.96
Systemic 15.35 (3.32-70.8
LEAR, Lower extremity arterial revascularization; CLI, critical limb isc
Anesthesiologists; BMI, body mass index.
Data are presented as n and (%), unless otherwise specified.
aNot prescribing medication concerning secondary prevention.
Univariate analysis was performed using 2 test and unpaired Student t test
characteristics that had a P value .05 in the univariate analysis. The effect
and AEs on the patients’ functional and living status and AEs were assess
confidence intervals (CI).sider LEAR in nonambulatory patients, our results suggestthat such procedures should be considered carefully, as
return to ambulatory status is almost never achievable.
Therefore, the consideration for LEAR in most of these
patients should be to improve the QOL by decreasing pain
level, sleep problems, and heal foot lesion in patients with
CLI.35,36
Prognostic factors for survival after primary LEAR
for CLI
Many studies have described increased mortality after
LEAR for CLI with risk factors such as diabetes, smok-
ing, cardiac disease, and cerebrovascular atherosclero-
sis.11,29,30,37,38 In this study, cardiac, pulmonary, carotid,
and renal disease, DM, and hypertension were correlated
with early death. The severity of limb ischemia is also an
important predictor of death rates.39 In this study, there
was also a correlation between the severity of ischemia
(Fontaine classification 4) and early death. Patients’
nonambulatory status at time of LEAR, not prescribing a
f CLI patient characteristics predicting for functional and
on Multivariate regression
P value OR 95% CI P value
.02
.04
.00 21.47 (2.76-166.77) .00
.01
.06
.00
.00 7.49 (2.17-25.80) .00
.00
.04
.02
.02
.05 4.67 (1.28-17.03) .02
.00 22.99 (6.27-84.24) .00
.03
.00
.02
.00 9.66 (1.84-50.57) .01
; OR, odds ratio; CI, confidence interval; ASA, American Society of
ultivariate logistic regression model was fitted that was based on all patient
ient characteristics, secondary prevention, functional status, reinterventions
ng the Cox regression model to estimate odds ratios (OR) and their 95%sis o
egressi
6)
)
.77)
)
)
)
)
)
)
)
)
)
3)
)
)
)
7)
hemia
. A m
of pat
ed usi-blocker, and the occurrence of systemic AEs were inde-
month
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AHA/ACC guidelines4,23 on perioperative care recom-
mend initiating -blocker treatment in patients with one or
more cardiovascular clinical risk factors. As stated in the
Table VI. Cumulative life-table primary and secondary pa
by preoperative functional status
1 month 6 months 12 months
BGP
Primary patency
All 91 (87.6) 76 (78.3) 66 (71.2)
Group I 34 (100) 31 (93.5) 29 (90.3)
Group II 57 (82.5) 45 (73.8) 37 (63.8)
Secondary patency
All 91 (93.3) 81 (85.1) 72 (81.6)
Group I 34 (100) 33 (93.3) 31 (90.9)
Group II 57 (90.9) 48 (81.2) 41 (77.3)
PTA
Primary patency
All 65 (96.8) 59 (96.8) 57 (91.6)
Group I 26 (100) 25 (100) 25 (100)
Group II 39 (94.7) 34 (94.7) 32 (85.7)
Limb salvage
All 106 (95.1) 93 (90.9) 85 (89.8)
Group I 42 (100) 41 (100) 41 (97.6)
Group II 64 (100) 52 (92.0) 44 (89.9)
Patient survival
All 106 (100) 98 (95.9) 94 (93.9)
Group I 42 (100) 41 (100) 41 (97.6)
Group II 64 (100) 57 (93.0) 53 (91.2)
BGP, Bypass graft procedure; PTA, percutaneous transluminal angioplasty;
Data are presented as at risk and (%), unless otherwise specified.
The Kaplan-Meier survival method was used to calculate the time curve of t
rates determined at regular intervals: 1-, 6-, 12-, 24-, 36-, 48-, 60- and 72-
survival rates.
Fig 4. Kaplan-Meier curve of the cumulative limb salvage rates of
all limbs stratified by preoperative ambulatory (n  42, 40%) and
nonambulatory (n  64, 60%) status after 6 years follow-up.literature,40 the occurrence of reinterventions (major am-putations) after primary LEAR was associated with signifi-
cantly worse long-term survival. The previously reported
5-year survival rate for CLI patients ranged from 12% to 64%,
with a mean of 45% to 60%.29,31-33 The survival rate of the
patients in this study of 59.2% at 6 years is similar to multiple
previous reports, with a 30-days mortality rate of 7%.
Evaluation of the optimal treatment of CLI: primary
LEAR - or major amputation
Nonambulatory patients have a significant decreased
chance of ambulatory status after LEAR due to their co-
morbidity, the occurrence of Aes, and reinterventions.
LEAR is preferable to primary major amputation in cost as
well as in allowing the patient to regain functional life.41-43
y rates, limb salvage, and patient survival rates stratified
months 36 months 48 months 60 months 72 months
0 (63.8) 50 (63.8) 43 (63.8) 42 (52.6) 31 (52.6)
8 (77.4) 24 (77.4) 23 (77.4) 23 (77.4) 22 (77.4)
2 (59.6) 26 (59.6) 20 (59.6) 19 (35.7) 9 (35.7)
9 (79.1) 63 (79.1) 56 (79.1) 55 (77.6) 50 (77.6)
0 (87.9) 29 (87.9) 28 (87.9) 28 (87.9) 27 (87.9)
9 (75.2) 34 (75.2) 28 (75.2) 27 (72.2) 23 (72.2)
2 (89.8) 47 (89.8) 44 (87.8) 43 (87.8) 36 (87.8)
4 (100) 24 (100) 23 (95.7) 22 (95.7) 21 (95.7)
8 (82.4) 23 (82.4) 21 (82.4) 21 (82.4) 15 (82.4)
2 (87.5) 73 (87.5) 65 (87.5) 64 (87.5) 56 (87.5)
0 (97.6) 40 (95.1) 39 (95.1) 39 (92.7) 38 (87.8)
2 (85.2) 33 (85.2) 26 (85.2) 25 (85.2) 18 (85.2)
2 (86.7) 85 (78.6) 77 (77.6) 76 (69.4) 68 (59.2)
0 (97.6) 40 (95.1) 39 (95.1) 39 (92.7) 38 (87.8)
2 (78.9) 45 (66.7) 38 (64.9) 37 (52.6) 30 (38.6)
I, ambulatory; group II, nonambulatory.
ulative primary - and secondary patency, limb salvage and patient survival
s after primary LEAR. The log-rank test was used for comparison of these
Table VII. Causes of death during follow-up: 30 days,
3, and 6 years
Cause of death Total 30 days 3 years 6 years
Cardiac 17 (35) 6 (35) 8 (47) 3 (18)
Pulmonary 3 (6) 0 (0) 3 (100) 0 (0)
Renal 2 (4) 0 (0) 1 (50) 1 (50)
Cerebral 2 (4) 1 (33) 0 (0) 1 (50)
Hemorrhage 3 (6) 1 (33) 0 (0) 2 (67)
Malignancy 2 (4) 0 (0) 0 (0) 2 (100)
Unknown 19 (40) 0 (0) 8 (42) 11 (58)
Total patients died 48 (100) 8 (16) 20 (42) 20 (42)
Data are presented as n and (%), unless otherwise specified.tenc
24
6
2
3
6
3
3
5
2
2
8
4
4
9
4
5
group
he cumHowever, the overall decision for limb salvage must also
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comes.25 Careful consideration should be focused on
chances of successful revascularization with subsequent
relief of pain and limb salvage vs repeated failed revascular-
ization attempts inducing increased patient morbidity and
ultimately major amputation. The ongoing topic of contro-
versy is primary LEAR vs primary major amputation, par-
ticularly in patients with CLI.12-14 As noted in the TASC
guidelines, there are patients who will benefit from primary
amputation rather than extensive LEAR. Subgroups of the
CLI patients currently undergoing extensive limb salvage
efforts may be better served with primary amputation.
Recent studies demonstrate that there appears to be no
difference in QOL or functional outcome between primary
LEAR and major amputation during follow-up.14-16 Also,
in selected high-risk patients an early primary major ampu-
tation may be preferred above weeks of hospitalization to
undergo repeated revascularization attempts and wound
treatment attempting to heal distal wounds. If subgroups
of CLI patients are better served by primary amputation,
how can they be identified? Several variables are to be taken
into account when deciding the type of treatment (primary
LEAR or major amputation) in case of CLI, such as:
functional status and independence, mental status (e.g.
dementia), comorbidity, pain, wound status (e.g. size and
complexity in the foot), fixed and unremediable flexion
contracture,4,23 technical issues of LEAR, nutritional status
and life expectancy. If salvage of a leg can keep it functional
for assisted transfers from bed to chair, rather than have a
patient who is a “dead lift” bedridden person who cannot
easily transfer to a chair, LEAR is good treatment option.
Limb salvage will continue to be the overriding goal for
Fig 5. Kaplan-Meier curve of the cumulative patient survival rates
stratified by preoperative ambulatory (n  42, 40%) and nonam-
bulatory (n  64, 60%) status after 6 years follow-up.most CLI patients referred to vascular therapy, but a subsetof these patients is clearly better served with a primary
major amputation.
Limitations and strength of the study
Several remarks have to be made concerning potential
limitations of this study. This study is limited by the relative
small cohort of high-risk patients who were referred to a
single center. Furthermore, since patients with previous
surgical treatment of CLI were excluded in this study,
results of our study cannot be extrapolated in this specific
patient category. However, to the best of our knowledge,
this is the first study to compare functional status before
and long-term (3 and 6 years) after LEAR for CLI with
detailed analysis of prognostic factors of morbidity and
mortality in this specific patient population.
CONCLUSION
Patients with good functional status before LEAR al-
most universally maintain this status 6 years after primary
LEAR. Preoperative nonambulatory high-risk comorbid
CLI patients infrequently experience improvement in func-
tional status after LEAR, they frequently experience AEs
and reinterventions, and have especially poor long-term
survival rates, emphasizing that attempts at limb salvage
must be carefully considered in these patients. Within our
multivariate analysis, we identified nonambulatory as an
independent predictive risk factor for post LEAR nonam-
bulatory status. Also pulmonary disease, not prescribing
-blockers, nonambulatory status, and systemic AEs were
independent predictive risk factors for early death. Sur-
geons and CLI patients should consider these variables to
inform decisionmaking when considering revascularization
in these high-risk settings.
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February 2010371.e1 Flu et alAppendix I, online only. Functional status (mobility/
type of transfer and locomotion) classified according to
the functional independence measure
Group Definition of the functional status
Ambulatory
group I
Another person is not needed to complete an
activity
Included independent/outside, restricted/
indoors, and assisted (with cane or walker).
Nonambulatory
group II
The patient can at least put forth half or more
of the energy to complete an activity or the
patient puts forth less than half the energy,
requires maximal or total assistance, or
even worse, the activity is not performed
at all
Included wheelchair dependent or bed-bound
patients.
Appendix II, online only. Classification of AEs and an
explanation of the causes of these AEs
Categorya
Cause of the AEb
(group 1-4)
Outcome
(category I-V)
Cardiac
Pulmonary
Neurology
Renal
(Sub)cutis
Muscles/
skeleton
Hematology
Vascular
Management
1 minor
2 surgical
3 failed
revascularization
4 systemic
I no consequence
II additional transfusion/
medication
III reoperation
IV irreversible physical
damage
V death
AE, Adverse event.
aGeneral definition of an AE.
An unintended and unwanted event or state occurring during or following
medical care, that is so harmful to a patient’s health that (adjustment of)
treatment is required or that permanent damage results. The AE may be
noted during hospitalization, until 30 days after discharge or transferee to
another department. The intended result of treatment, the likelihood of the
adverse outcome occurring, and the presence or absence of a medical error
causing it, is irrelevant in identifying an adverse outcome.
bExplanation and definition of the causes of perioperative AEs.
Minor: an AE such as: urinary tract infection, deep venous thrombosis.
Surgical: an AE due to surgical treatment, such as: abscess, wound infection,
wound necrosis, wound dehiscence, hemorrhage.
Failed revascularization: when a primary bypass graft occluded, or at risk for
occlusion and surgical or endovascular reintervention was performed. It was
also defined when an anatomical arterial segment occluded after a PTA was
performed on that same segment.
Systemic: potential life threatening AEs, such as: pneumonia, respiratory
failure, arrhythmia, cardiac arrest, cardiogenic shock, congestive heart fail-
ure, myocardial infarction, shock, stroke.Appendix III, online only. Subdivision of specific AE
categories
Cardiac
Congestive heart failure
Arrhythmia
Cardiac arrest
Myocardial infarction
Endocarditis/pericarditis
Cardiogenic shock
Hypertension/hypotension
Tachycardia/bradycardia
Pulmonary
Respiratory insufficiency
Aspiration/pneumonia
Pleural fluid
Atelectasis
Embolism
Neurology
Cerebrovascular accident
Transient ischemic attack
Neuropraxia
Renal
Renal failure
End-stage renal disease
Urinary tract infection
Urinary retention
Pyelonefritis/hydronefritis
(Sub)cutis
Blister/ulcer
Abscess
Epidermolysis
Seroma
Cellulites
Wound hematoma
Wound infection
Wound dehiscence
Necrosis/unexpected tissue loss
Muscles/skeleton
Compartmental syndrome
Osteomyelitis
Hematology
Spontaneous hemorrhage
Heparin induced thrombocytopenia
Transfusion reaction
Decrease hemoglobin
Thrombosis from ATIII, or protein C or S deficiency
Septicemia
Fluid and electrolytes
Vascular management
Line infection
Deep venous thrombosis
Infection BGP
Stenosis BGP/anatomical segment after PTA
Occlusion BGP/anatomical segment after PTA
Anastomotic pseudoaneurysm/anatomical segment after PTA
Hemorrhage
General management
Error in medication/in diagnosis/in judgment/in technique
Delay to OR/in MD response/in diagnosis
Incomplete hospital record
BGP, Bypass graft procedure; PTA, percutaneous transluminal angioplasty;
OR, operating room; MD, medical doctor.
